BioVeris
This article was originally published in The Gray Sheet
Executive Summary
Settlement pact resolves all outstanding disputes between the firm and Meso Scale Diagnostics (MSD) - a joint venture between BioVeris and Meso Scale Technologies (MST) - as well as with MST CEO Jacob Wohlstadter. The deal includes a $5 mil. payment to MSD and an agreement for MSD or MST to purchase BioVeris' interest in MSD. BioVeris also gained sales data on the joint venture needed to file financial statements. The firm's delay in filing a 10-K for fiscal 2004 (ended March 31) with the SEC led to a July Nasdaq delisting notice (1"The Gray Sheet" July 26, 2004, p. 11)...
You may also be interested in...
Meso Scale Diagnostics CEO Prompts BioVeris Nasdaq Delistment
BioVeris will file a request by August for a Nasdaq Listing Qualifications Panel to review a staff determination and stay the firm's stock delistment
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.